Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 36.26 Million USD | 126.29% |
| 2022 | 16.02 Million USD | -27.24% |
| 2021 | 22.02 Million USD | -17.51% |
| 2020 | 26.7 Million USD | 42.33% |
| 2019 | 18.76 Million USD | -75.46% |
| 2018 | 76.44 Million USD | -30.86% |
| 2017 | 110.55 Million USD | 37.36% |
| 2016 | 80.48 Million USD | 65.37% |
| 2015 | 48.67 Million USD | 136.97% |
| 2014 | 20.53 Million USD | 39.78% |
| 2013 | 14.69 Million USD | 19.12% |
| 2012 | 12.33 Million USD | -5.25% |
| 2011 | 13.01 Million USD | 54.35% |
| 2010 | 8.43 Million USD | 68.13% |
| 2009 | 5.01 Million USD | -9.08% |
| 2008 | 5.51 Million USD | 15.98% |
| 2007 | 4.75 Million USD | 36.65% |
| 2006 | 3.48 Million USD | 45.33% |
| 2005 | 2.39 Million USD | 268.34% |
| 2004 | 650.31 Thousand USD | 6403.1% |
| 2003 | 10 Thousand USD | 0.0% |
| 2002 | 10 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 7.13 Million USD | -15.97% |
| 2023 Q4 | 8.78 Million USD | 23.12% |
| 2023 FY | 36.26 Million USD | 126.29% |
| 2023 Q1 | 11.86 Million USD | 22.01% |
| 2023 Q2 | 8.48 Million USD | -28.5% |
| 2022 Q1 | 3.25 Million USD | -21.9% |
| 2022 Q2 | 7.84 Million USD | 141.08% |
| 2022 FY | 16.02 Million USD | -27.24% |
| 2022 Q4 | 9.72 Million USD | -3.5% |
| 2022 Q3 | 10.08 Million USD | 28.58% |
| 2021 Q1 | 9.22 Million USD | -2.27% |
| 2021 Q3 | 4.36 Million USD | -59.04% |
| 2021 FY | 22.02 Million USD | -17.51% |
| 2021 Q4 | 4.16 Million USD | -4.6% |
| 2021 Q2 | 10.65 Million USD | 15.49% |
| 2020 Q2 | 6.61 Million USD | 2.7% |
| 2020 Q4 | 9.44 Million USD | 85.57% |
| 2020 FY | 26.7 Million USD | 42.33% |
| 2020 Q1 | 6.43 Million USD | 19.62% |
| 2020 Q3 | 5.08 Million USD | -23.06% |
| 2019 Q2 | 4.46 Million USD | 23.89% |
| 2019 Q1 | 3.6 Million USD | -61.59% |
| 2019 Q3 | 5.31 Million USD | 19.22% |
| 2019 FY | 18.76 Million USD | -75.46% |
| 2019 Q4 | 5.38 Million USD | 1.24% |
| 2018 Q3 | 23.24 Million USD | 51.97% |
| 2018 Q1 | 15.29 Million USD | -32.31% |
| 2018 FY | 76.44 Million USD | -30.86% |
| 2018 Q4 | 9.37 Million USD | -59.68% |
| 2018 Q2 | 15.29 Million USD | -0.03% |
| 2017 FY | 110.55 Million USD | 37.36% |
| 2017 Q1 | 24.08 Million USD | 14.84% |
| 2017 Q2 | 35.86 Million USD | 48.88% |
| 2017 Q4 | 22.6 Million USD | -23.72% |
| 2017 Q3 | 29.63 Million USD | -17.37% |
| 2016 Q2 | 16.56 Million USD | 6.24% |
| 2016 FY | 80.48 Million USD | 65.37% |
| 2016 Q4 | 20.97 Million USD | -25.42% |
| 2016 Q3 | 28.12 Million USD | 69.78% |
| 2016 Q1 | 15.59 Million USD | -22.81% |
| 2015 Q4 | 20.2 Million USD | 40.04% |
| 2015 FY | 48.67 Million USD | 136.97% |
| 2015 Q2 | 13.62 Million USD | -1.52% |
| 2015 Q3 | 14.42 Million USD | 5.84% |
| 2015 Q1 | 13.83 Million USD | 104.25% |
| 2014 Q4 | 6.77 Million USD | 35.91% |
| 2014 Q1 | 3.59 Million USD | -39.64% |
| 2014 FY | 20.53 Million USD | 39.78% |
| 2014 Q3 | 4.98 Million USD | -16.89% |
| 2014 Q2 | 5.99 Million USD | 66.83% |
| 2013 FY | 14.69 Million USD | 19.12% |
| 2013 Q4 | 5.95 Million USD | 49.61% |
| 2013 Q3 | 3.98 Million USD | 30.41% |
| 2013 Q1 | 5.47 Million USD | 151.11% |
| 2013 Q2 | 3.05 Million USD | -44.24% |
| 2012 Q3 | 2.27 Million USD | -36.44% |
| 2012 Q4 | 2.18 Million USD | -4.23% |
| 2012 FY | 12.33 Million USD | -5.25% |
| 2012 Q1 | 3.22 Million USD | -0.45% |
| 2012 Q2 | 3.58 Million USD | 10.94% |
| 2011 Q2 | 3.59 Million USD | 5.53% |
| 2011 FY | 13.01 Million USD | 54.35% |
| 2011 Q4 | 3.24 Million USD | 6.58% |
| 2011 Q1 | 3.4 Million USD | 14.77% |
| 2011 Q3 | 3.04 Million USD | -15.37% |
| 2010 Q2 | 1.97 Million USD | 6.05% |
| 2010 Q1 | 1.86 Million USD | 17.51% |
| 2010 Q3 | 3 Million USD | 52.13% |
| 2010 Q4 | 2.96 Million USD | -1.26% |
| 2010 FY | 8.43 Million USD | 68.13% |
| 2009 FY | 5.01 Million USD | -9.08% |
| 2009 Q4 | 1.58 Million USD | -22.9% |
| 2009 Q2 | 1.46 Million USD | 89.33% |
| 2009 Q1 | 772.28 Thousand USD | 6.58% |
| 2009 Q3 | 2.05 Million USD | 40.73% |
| 2008 Q2 | 1.26 Million USD | -22.84% |
| 2008 Q4 | 724.62 Thousand USD | -37.73% |
| 2008 Q3 | 1.16 Million USD | -7.83% |
| 2008 Q1 | 1.63 Million USD | 12.49% |
| 2008 FY | 5.51 Million USD | 15.98% |
| 2007 Q2 | 820.92 Thousand USD | -46.46% |
| 2007 Q3 | 1.06 Million USD | 29.58% |
| 2007 Q4 | 1.45 Million USD | 36.76% |
| 2007 FY | 4.75 Million USD | 36.65% |
| 2007 Q1 | 1.53 Million USD | 14.5% |
| 2006 Q4 | 1.33 Million USD | 42.62% |
| 2006 Q1 | 1.05 Million USD | 31.98% |
| 2006 FY | 3.48 Million USD | 45.33% |
| 2006 Q2 | 688.75 Thousand USD | -34.69% |
| 2006 Q3 | 938.96 Thousand USD | 36.33% |
| 2005 Q4 | 798.99 Thousand USD | 37.3% |
| 2005 Q3 | 581.94 Thousand USD | -31.21% |
| 2005 Q1 | 722.35 Thousand USD | 194.69% |
| 2005 FY | 2.39 Million USD | 268.34% |
| 2005 Q2 | 845.9 Thousand USD | 17.1% |
| 2004 Q4 | 245.12 Thousand USD | 0.0% |
| 2004 FY | 650.31 Thousand USD | 6403.1% |
| 2003 FY | 10 Thousand USD | 0.0% |
| 2002 FY | 10 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2615.678% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -619.272% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -22.715% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1526.366% |
| Rebus Holdings, Inc. | 664 Thousand USD | -5361.747% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 2.656% |
| Qrons Inc. | 643.67 Thousand USD | -5534.192% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -9209.334% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 36.863% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -8628.72% |
| Skye Bioscience, Inc. | 13.54 Million USD | -167.694% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 58.212% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -637.427% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -13756.476% |
| SQZ Biotechnologies Company | 85.61 Million USD | 57.643% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1143.59% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2314.676% |
| Mesoblast Limited | 5.9 Million USD | -514.47% |
| Marizyme, Inc. | 19.23 Million USD | -88.494% |
| Genus plc | 147.7 Million USD | 75.446% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -313.088% |
| Pharming Group N.V. | 225.49 Million USD | 83.917% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1670.191% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2603.301% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -334.896% |
| ContraFect Corporation | 56.88 Million USD | 36.251% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -722.606% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2352.473% |
| IMV Inc. | 37.7 Million USD | 3.827% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1199.69% |
| MultiCell Technologies, Inc. | 567.42 USD | -6391285.57% |
| ONE Bio Corp. | 6.44 Million USD | -462.797% |
| Accustem Sciences Inc. | 3.74 Million USD | -868.018% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 57.803% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -6717.404% |
| Q BioMed Inc. | 3.43 Million USD | -955.279% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -46.737% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1280.236% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3547.823% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 63.489% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1960.945% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -439.832% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1845.215% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 145164.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -126.518% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1876.246% |
| GB Sciences, Inc. | 1.42 Million USD | -2453.029% |
| Alpha Cognition Inc. | 9.7 Million USD | -273.661% |
| HST Global, Inc. | 140.9 Thousand USD | -25637.543% |
| CSL Limited | 3.44 Billion USD | 98.949% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -3123.902% |
| Halberd Corporation | 74.84 Thousand USD | -48356.749% |
| Enzolytics Inc. | 2.17 Million USD | -1563.954% |
| Agentix Corp. | 1.37 Million USD | -2543.765% |
| Resverlogix Corp. | 12.71 Million USD | -185.289% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -893.397% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 97.635% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3373.755% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1407.983% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2196.254% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -965.087% |
| AVAX Technologies, Inc. | 7.31 Million USD | -396.097% |
| Zenith Capital Corp. | 8.94 Million USD | -305.524% |
| Genscript Biotech Corporation | 825.34 Million USD | 95.606% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -208074.043% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1377.039% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -21045.246% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1787.963% |
| Kadimastem Ltd | 2.41 Million USD | -1404.743% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1739.015% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -233.726% |
| BioStem Technologies, Inc. | 22.97 Million USD | -57.851% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -19882.919% |
| LadRx Corporation | 3.81 Million USD | -851.416% |
| Cell Source, Inc. | 4.32 Million USD | -738.453% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3826.974% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3826.974% |
| NovAccess Global Inc. | 2.46 Million USD | -1370.187% |
| Affymax, Inc. | 39.38 Million USD | 7.922% |
| Itoco Inc. | 919.14 Thousand USD | -3845.632% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -755.65% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -3140.929% |
| Mobile Lads Corp. | 554.54 Thousand USD | -6439.764% |
| CytoDyn Inc. | 18.05 Million USD | -100.831% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -143989.952% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -16378.703% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2454.318% |
| SYBLEU INC | 160.87 Thousand USD | -22442.828% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1896.675% |
| International Stem Cell Corporation | 5.27 Million USD | -588.029% |
| Bioxytran, Inc. | 3.82 Million USD | -849.335% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -68791.759% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -178172.624% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -2141.409% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -4828.551% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1065.734% |
| Neutra Corp. | 243.82 Thousand USD | -14774.026% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -107.745% |
| PureTech Health plc | 144.59 Million USD | 74.919% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -76.995% |
| IXICO plc | 4.7 Million USD | -670.47% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -312.254% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 69.2% |
| CSL Limited | 3.89 Billion USD | 99.068% |
| Cellectis S.A. | 97.32 Million USD | 62.735% |